Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors

Hypertension Research

Volumn 34, Issue 2, 2011, Pages 225-231

  Ise, Takayuki ^a   Aihara, Ken Ichi ^a   Sumitomo Ueda, Yuka ^a   Yoshida, Sumiko ^a   Ikeda, Yasumasa ^a   Yagi, Shusuke ^a   Iwase, Takashi ^a   Yamada, Hirotsugu ^a   Akaike, Masashi ^a   Sata, Masataka ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

diastolic dysfunction; heparin cofactor II; left atrial volume; thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN COFACTOR II; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; DECELERATION TIME; DIASTOLIC DYSFUNCTION; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; LEFT ATRIAL VOLUME INDEX; MAJOR CLINICAL STUDY; MALE; RELATIVE WALL THICKNESS; SYSTOLIC HEART FAILURE;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEPARIN COFACTOR II; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VENTRICULAR DYSFUNCTION; VENTRICULAR REMODELING;

EID: 79751520386     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.211     Document Type: Article

References (41)

1. Narayanan S. Multifunctional roles of thrombin. Ann Clin Lab Sci 1999; 29: 275-280. (Pubitemid 29505961)
2. Bar-Shavit R, Kahn A, Wilner GD, Fenton II JW. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science 1983; 220: 728-731. (Pubitemid 13081951)
3. Chen LB, Buchanan JM. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975; 72: 131-135.
4. McNamara CA, Sarembock IJ, Gimple LW, Fenton II JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-98. (Pubitemid 23037258)
5. Derian CK, Damiano BP, D'Andrea MR, Andrade-Gordon P. Thrombin regulation of cell function through protease-activated receptors: implications for therapeutic intervention. Biochemistry (Mosc) 2002; 67: 56-64.
6. Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 27-36. (Pubitemid 46370476)
7. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90: 1614-1621.
8. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74: 1209-1214.
9. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-219. (Pubitemid 34083741)
10. Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, Tamura K, Matsumoto T. High plasma heparin cofactor II activity is associated with reduced incidence of in-stent restenosis after percutaneous coronary intervention. Circulation 2004; 109: 481-486. (Pubitemid 38168510)
11. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, Yoshida T, Hashizume S, Kato M, Yamaguchi H, Kato S, Ikeda Y, Arase T, Kondo A, Matsumoto T. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 2004; 109: 2761-2765. (Pubitemid 38744553)
12. Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. Arterioscler Thromb Vasc Biol 2007; 27: 454-460.
13. Vicente CP, He L, Tollefsen DM. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Blood 2007; 110: 4261-4267. (Pubitemid 351377790)
14. Aihara K, Azuma H, Akaike M, Ikeda Y, Sata M, Takamori N, Yagi S, Iwase T, Sumitomo Y, Kawano H, Yamada T, Fukuda T, Matsumoto T, Sekine K, Sato T, Nakamichi Y, Yamamoto Y, Yoshimura K, Watanabe T, Nakamura T, Oomizu A, Tsukada M, Hayashi H, Sudo T, Kato S. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. J Clin Invest 2007; 117: 1514-1526. (Pubitemid 46871336)
15. Aihara K, Azuma H, Akaike M, Sata M, Matsumoto T. Heparin cofactor II as a novel vascular protective factor against atherosclerosis. J Atheroscler Thromb 2009; 16: 523-531.
16. Aihara K, Azuma H, Akaike M, Kurobe H, Takamori N, Ikeda Y, Sumitomo Y, Yoshida S, Yagi S, Iwase T, Ishikawa K, Sata M, Kitagawa T, Matsumoto T. Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors. J Atheroscler Thromb 2009; 16: 127-134.
17. Tsang TS, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, Cha SS, Seward JB. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol 2006; 47: 1018-1023.
18. Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol 1999; 84: 829-832. (Pubitemid 29469795)
19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quanti- fication Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463. (Pubitemid 41821197)
20. Aurigemma GP, Gottdiener JS, Arnold AM, Chinali M, Hill JC, Kitzman D. Left atrial volume and geometry in healthy aging: the Cardiovascular Health Study. Circ Cardiovasc Imaging 2009; 2: 282-289.
21. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618. (Pubitemid 8066109)
22. Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202. (Pubitemid 36068707)
23. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. J AmColl Cardiol 2003; 41: 1036-1043. (Pubitemid 36315550)
24. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, Diamond PM, Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001; 76: 467-475. (Pubitemid 32423130)
25. Lim TK, Dwivedi G, Hayat S, Majumdar S, Senior R. Independent value of left atrial volume index for the prediction of mortality in patients with suspected heart failure referred from the community. Heart 2009; 95: 1172-1178.
26. Rao AK, Djamali A, Korcarz CE, Aeschlimann SE, Wolff MR, Stein JH. Left atrial volume is associated with inflammation and atherosclerosis in patients with kidney disease. Echocardiography 2008; 25: 264-269. (Pubitemid 351326828)
27. Saura D, Marin F, Climent V, Gonzalez J, Roldan V, Hernandez-Romero D, Oliva MJ, Sabater M, de la Morena G, Lip GY, Valdes M. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling. Int J Clin Pract 2009; 63: 1465-1471.
28. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-1955.
29. Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol 2006; 47: 500-506. (Pubitemid 43170836)
30. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533. (Pubitemid 27486472)
31. Sohn DW, Chung WY, Chai IH, Zo JH, Lee MM, Park YB, Choi YS, Lee YW. Mitral annulus velocity in the noninvasive estimation of left ventricular peak dP/dt. Am J Cardiol 2001; 87: 933-936.
32. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788-1794.
33. Yamamoto T, Oki T, Yamada H, Tanaka H, Ishimoto T, Wakatsuki T, Tabata T, Ito S. Prognostic value of the atrial systolic mitral annular motion velocity in patients with left ventricular systolic dysfunction. J Am Soc Echocardiogr 2003; 16: 333-339. (Pubitemid 36397603)
34. Sabri A, Muske G, Zhang H, Pak E, Darrow A, Andrade-Gordon P, Steinberg SF. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res 2000; 86: 1054-1061. (Pubitemid 30367864)
35. Sabri A, Short J, Guo J, Steinberg SF. Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes. Circ Res 2002; 91: 532-539.
36. Moshal KS, Tyagi N, Moss V, Henderson B, Steed M, Ovechkin A, Aru GM, Tyagi SC. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med 2005; 9: 704-713. (Pubitemid 44151958)
37. Moshal KS, Tyagi N, Henderson B, Ovechkin AV, Tyagi SC. Protease-activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol 2005; 288: H2770-H2777. (Pubitemid 40720657)
38. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade- Gordon P, Kotzsch M, Spring D, Luther T, Abe J, Pohlman TH, Verrier ED, Blaxall BC, Mackman N. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 2007; 116: 2298-2306. (Pubitemid 350100336)
39. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
40. Marinissen MJ, Servitja JM, Offermanns S, Simon MI, Gutkind JS. Thrombin protease-activated receptor-1 signals through Gq- and G13-initiated MAPK cascades regulating c-Jun expression to induce cell transformation. J Biol Chem 2003; 278: 46814-46825. (Pubitemid 37452261)
41. Sumitomo-Ueda Y, Aihara K, Ise T, Yoshida S, Ikeda Y, Uemoto R, Yagi S, Iwase T, Ishikawa K, Hirata Y, Akaike M, Sata M, Kato S, Matsumoto T. Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice. Hypertension 2010; 56: 430-436.